Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | INPP5D | Q92835 | 2/20 | 0.98 |
| ▸ | CDC25A | P30304 | 4/20 | 0.65 |
| ▸ | BCHE | P06276 | 1/20 | 0.64 |
| ▸ | ACHE | P22303 | 1/20 | 0.64 |
| ▸ | POLA1 | P09884 | 1/20 | 0.64 |
| ▸ | OSBP | P22059 | 1/20 | 0.59 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.57 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.57 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.57 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | CASP7 | P55210 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8021037 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP2C19INPP5DCDC25ABCHE | |
| SCHEMBL20004917 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP2C19INPP5DCDC25ABCHE | |
| SCHEMBL18541453 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP2C19INPP5DCDC25ABCHE | |
| SCHEMBL21946613 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP2C19INPP5DCDC25ABCHE | |
| SCHEMBL23016826 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP2C19INPP5DCDC25ABCHE | |
| SCHEMBL23645781 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP2C19INPP5DCDC25ABCHE | |
| SCHEMBL22712829 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP2C19INPP5DCDC25ABCHE | |
| SCHEMBL24104271 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP2C19INPP5DCDC25ABCHE | |
| SCHEMBL21589991 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP2C19INPP5DCDC25ABCHE | |
| SCHEMBL14160673 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP2C19INPP5DCDC25ABCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333698-A1 | SIRPa DEFICIENT MACROPHAGES FOR TREATING CANCER | UNIV GEORGIA STATE RES FOUND (US) | 2025-10-30 | — | — | US | claimed |
| EP-4423251-A1 | SIRP ALPHA DEFICIENT MACROPHAGES FOR TREATING CANCER | Georgia State University Research Foundation, Inc. (US) | 2024-09-04 | — | — | EP | claimed |
| US-20230220342-A1 | SIRPa Deficient Macrophages for Treating Cancer | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-07-13 | — | — | US | claimed |
| WO-2023076813-A1 | SIRPα DEFICIENT MACROPHAGES FOR TREATING CANCER | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2023-05-04 | — | — | WO | claimed |
| EP-4139003-A1 | SIRPa DEFICIENT MACROPHAGES FOR TREATING CANCER | Georgia State University Research Foundation, Inc. (US) | 2023-03-01 | — | — | EP | claimed |
| US-8889631-B2 | Disruptors of early/recycling endosomes | THE UNIVERSITY OF KANSAS (US) | 2014-11-18 | — | — | US | claimed |
| WO-2010022051-A2 | DISRUPTORS OF EARLY/RECYCLING ENDOSOMES | UNIVERSITY OF KANSAS (US) | 2010-02-25 | — | — | WO | claimed |
| US-20100041773-A1 | DISRUPTORS OF EARLY/RECYCLING ENDOSOMES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-18 | — | — | US | claimed |
| US-20250333698-A1 | SIRPa DEFICIENT MACROPHAGES FOR TREATING CANCER | UNIV GEORGIA STATE RES FOUND (US) | 2025-10-30 | — | — | US | disclosed |
| EP-4423251-A1 | SIRP ALPHA DEFICIENT MACROPHAGES FOR TREATING CANCER | Georgia State University Research Foundation, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20230391817-A1 | 5ALPHA-HYDROXY-6BETA-[2-(1-H-IMIDAZOL-4-YL)-ETHYLAMINO]-CHOLESTAN-3BETA-OL ANALOGUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME FOR USE IN THE TREATMENT OF CANCER | DENDROGENIX (BE) | 2023-12-07 | — | — | US | disclosed |
| CN-116615202-A | 5 alpha-hydroxy-6 beta- [2- (1H-imidazol-4-yl) ethylamino ] -cholestan-3 beta-ol analogues for the treatment of cancer and pharmaceutical compositions comprising the same | 登德罗杰尼克斯公司 | 2023-08-18 | — | — | CN | disclosed |
| US-20230220342-A1 | SIRPa Deficient Macrophages for Treating Cancer | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-07-13 | — | — | US | disclosed |
| WO-2023076813-A1 | SIRPα DEFICIENT MACROPHAGES FOR TREATING CANCER | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| EP-0680623-A4 | CHEMICAL FUNCTIONALIZATION OF SURFACES. | OREGON STATE (US) | 1996-07-24 | — | — | EP | disclosed |
| WO-1996018372-A2 | CATIONIC AMPHIPHILES AND PLASMIDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | GENZYME CORPORATION (US) | 1996-06-20 | — | — | WO | disclosed |
| EP-0680623-A1 | CHEMICAL FUNCTIONALIZATION OF SURFACES | THE STATE OF OREGON ACTING BY AND THROUGH THE OREGON STATEBOARD OF HIGHER EDUCATION ON BEHALF OF OREGON STATE UNIVERSITY (US) | 1995-11-08 | — | — | EP | disclosed |
| US-5465151-A | Sensors employing interference of electromagnetic waves passing through waveguides having functionalized surfaces | STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF OREGON (US) | 1995-11-07 | — | — | US | disclosed |
| WO-1994017447-A1 | CHEMICAL FUNCTIONALIZATION OF SURFACES | THE STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF OREGON (US) | 1994-08-04 | — | — | WO | disclosed |
| CN-1081682-A | Steroid derivatives | LILLY CO ELI (US) | 1994-02-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391817-A1 | 5ALPHA-HYDROXY-6BETA-[2-(1-H-IMIDAZOL-4-YL)-ETHYLAMINO]-CHOLESTAN-3BETA-OL ANALOGUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME FOR USE IN THE TREATMENT OF CANCER | CYP46A1, CYP27A1, DHCR7 | CYP2D6 405/4885CYP2C19 1058/4885INPP5D 293/4885 |
| US-20100041773-A1 | DISRUPTORS OF EARLY/RECYCLING ENDOSOMES | EEA1, NSF, LAMP2 | CYP2D6 4832/4885CYP2C19 4885/4885INPP5D 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.